Literature DB >> 8857074

A limited sampling method to estimate methotrexate pharmacokinetics in patients with rheumatoid arthritis using a Bayesian approach and the population data modeling program P-PHARM.

F Bressolle1, C Bologna, L Edno, J C Bernard, R Gomeni, J Sany, B Combe.   

Abstract

This paper describes a methodology to calculate methotrexate (MTX) pharmacokinetic parameters after intramuscular administration using two samples and the population parameters. Total and free MTX were measured over a 36-h period in 56 rheumatoid arthritis patients; 14 patients were studied after a two-dose scheme at 15-day intervals. The Hill equation was used to relate the free MTX to the total MTX changes in plasma concentrations, and a two-compartment open model was used to fit the total MTX plasma concentrations. A non-linear mixed effect procedure was used to estimate the population parameters and to explore the interindividual variability in relation to the following covariables: age, weight, height, haemoglobin, erythrocyte sedimentation rate, platelet count, creatinine clearance, rheumatoid factor, C-reactive protein, swelling joint count, and Ritchie's articular index. Population parameters were evaluated for 40 patients using a three-step approach. The population average parameters and the interindividual variabilities expressed as coefficients of variation (CV%) were: CL, 6.94 l center dot h-1 (20.5%); V, 34.8 l (32.2%); k12, 0.0838 h-1 (47.7%); k21, 0.0769 h-1 (61.6%); ka, 4.31 h-1 (58%); Emax, 1.12 mu mol center dot l-1 (19.7%); gamma, 0.932 (12.3%); and EC50, 2.14 mu mol center dot l-1 (27.3%). Thirty additional data sets (16 new patients and 14 patients of the previous population but treated on a separate occasion) were used to evaluate the predictive performance of the population parameters. Twelve blood samples were collected from each individual in order to calculate individual parameters using standard fitting procedures. These values were compared to the ones estimated using a Bayesian approach with population parameters as a priori information together with two samples, selected from the individual observations. The results show that the bias was not statistically different from zero and the precision of these parameters was excellent.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8857074     DOI: 10.1007/bf00226329

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  32 in total

1.  Estimate of the number and of the temporal sequence of measurements in a kinetic experiment.

Authors:  R Gomeni
Journal:  Fundam Clin Pharmacol       Date:  1990       Impact factor: 2.748

2.  Low dose MTX and NSAID induced "mild" renal insufficiency and severe neutropenia.

Authors:  A Kraus; D Alarcón-Segovia
Journal:  J Rheumatol       Date:  1991-08       Impact factor: 4.666

3.  Pharmacokinetics of low-dose methotrexate in rheumatoid arthritis patients.

Authors:  R A Herman; P Veng-Pedersen; J Hoffman; R Koehnke; D E Furst
Journal:  J Pharm Sci       Date:  1989-02       Impact factor: 3.534

4.  Variability in individual responses of 532 patients with rheumatoid arthritis to first-line and second-line drugs.

Authors:  T Pincus; L F Callahan
Journal:  Agents Actions Suppl       Date:  1993

5.  Evaluation of methods for estimating population pharmacokinetic parameters. II. Biexponential model and experimental pharmacokinetic data.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1981-10

6.  Comparison of serum concentrations of methotrexate after various routes of administration.

Authors:  M Freeman-Narrod; B J Gerstley; P F Engstrom; R S Bornstein
Journal:  Cancer       Date:  1975-11       Impact factor: 6.860

7.  Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. A metaanalysis of published clinical trials.

Authors:  D T Felson; J J Anderson; R F Meenan
Journal:  Arthritis Rheum       Date:  1992-10

8.  Low-dose methotrexate kinetics in arthritis.

Authors:  J Edelman; D F Biggs; F Jamali; A S Russell
Journal:  Clin Pharmacol Ther       Date:  1984-03       Impact factor: 6.875

9.  Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis. 84-month update.

Authors:  M E Weinblatt; B N Weissman; D E Holdsworth; P A Fraser; A L Maier; K R Falchuk; J S Coblyn
Journal:  Arthritis Rheum       Date:  1992-02

Review 10.  The pharmacology of methotrexate.

Authors:  E A Olsen
Journal:  J Am Acad Dermatol       Date:  1991-08       Impact factor: 11.527

View more
  5 in total

Review 1.  Adaptive control methods for the dose individualisation of anticancer agents.

Authors:  A Rousseau; P Marquet; J Debord; C Sabot; G Lachâtre
Journal:  Clin Pharmacokinet       Date:  2000-04       Impact factor: 6.447

2.  Use of methotrexate in older patients. A risk-benefit assessment.

Authors:  S E Tett; E J Triggs
Journal:  Drugs Aging       Date:  1996-12       Impact factor: 3.923

Review 3.  Pharmacokinetics and pharmacodynamics of methotrexate in non-neoplastic diseases.

Authors:  Jirí Grim; Jaroslav Chládek; Jirina Martínková
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

4.  The population pharmacokinetics of long-term methotrexate in rheumatoid arthritis.

Authors:  C Godfrey; K Sweeney; K Miller; R Hamilton; J Kremer
Journal:  Br J Clin Pharmacol       Date:  1998-10       Impact factor: 4.335

5.  Population pharmacokinetics of raltitrexed in patients with advanced solid tumours.

Authors:  Elaine Y L Blair; Laurent P Rivory; Stephen J Clarke; Andrew J McLachlan
Journal:  Br J Clin Pharmacol       Date:  2004-04       Impact factor: 4.335

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.